Look up one drug

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

Mint-Atorvastatin · DIN 02479508 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2020-04-30 Health Canada: Marketed since 2022-11-08 · brand MINT-ATORVASTATIN · ATC C10AA05 ATORVASTATIN · form Tablet · route Oral · ingredients ATORVASTATIN (ATORVASTATIN CALCIUM) 10 MG · company Mint pharmaceuticals inc · schedule Prescription

DIN 02479508: Mint-Atorvastatin Raw flags: chronicUseMed=Y, sec3=Y Item: 240600036; group id 296; item number 0646; lccId None; manufacturer id MIN Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1743; ministry $0.1743 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02479508 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97017

Interchangeable products

AG-Atorvastatin · DIN 02478145 · $0.1743 Ach-Atorvastatin Calcium · DIN 02457741 · $0.1743 Apo-Atorvastatin · DIN 02295261 · $0.1743 Atorvastatin · DIN 02348705 · $0.1743 Atorvastatin · DIN 02475022 · $0.1743 Atorvastatin · DIN 02545462 · $0.1743 Atorvastatin-10 · DIN 02411350 · $0.1743 Auro-Atorvastatin · DIN 02407256 · $0.1743 Bio-Atorvastatin · DIN 02481189 · $0.1743 Jamp Atorvastatin Calcium · DIN 02504197 · $0.1743 Jamp-Atorvastatin · DIN 02391058 · $0.1743 Lipitor · DIN 02230711 · $0.1743 M-Atorvastatin · DIN 02471167 · $0.1743 Mar-Atorvastatin · DIN 02454017 · $0.1743 Mylan-Atorvastatin · DIN 02392933 · $0.1743 NRA-Atorvastatin · DIN 02476517 · $0.1743 PMS-Atorvastatin · DIN 02477149 · $0.1743 PMSC-Atorvastatin · DIN 02507234 · $0.1743 PRZ-Atorvastatin · DIN 02521555 · $0.1743 Ratio-Atorvastatin · DIN 02350297 · $0.1743 Reddy-Atorvastatin · DIN 02417936 · $0.1743 Sandoz Atorvastatin · DIN 02324946 · $0.1743 Taro-Atorvastatin · DIN 02313707 · $0.1743 Teva-Atorvastatin · DIN 02310899 · $0.1743

Shortage status: not checked (no credentials)